Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178163 · ClinicalTrials.gov registry record · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
A NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 1,020
- Enrollment target
- 11
- Study locations
NCT02178163: Recruiting NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT02178163 is a NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 1,020 participants, above the 645-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (58% higher). The trial reports 11 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02178163, a NA study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-small Cell Lung Cancer, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,020 participants
- Enrollment target
- 11
- Study locations
Study Summary
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.
Primary Outcome
Will be estimated with 95% confidence interval (CI) using the Wilson's method.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
Study Locations (11)
Michigan
- KCI at McLaren Bay Region - Bay City
- KCI at Mclaren Bloomfield Hills - Bloomfield Hills
- KCI At McLaren Clarkston - Clarkston
- Barbara Ann Karmanos Cancer Institute - Detroit
- KCI at McLaren Flint - Flint
- KCI at McLaren Greater Lansing, Mid Michigan Physicians - Lansing
- KCI at McLaren Lapeer Region - Lapeer
- KCI at McLaren Macomb - Mount Clemens
- KCI at McLaren Central Michigan - Mount Pleasant
- KCI at Northern Michigan - Petoskey
- KCI at McLaren Port Huron - Port Huron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT02178163 shows while recruiting
NCT02178163 is an interventional study that assigns participants to a tested intervention. Its 1,020 participants enrollment target places it among the larger protocols in the corpus, above the 645-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (58% higher).
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02178163 lists 11 locations in 1 state (Michigan).
Frequently Asked Questions
What is clinical trial NCT02178163 about?
NCT02178163 is a clinical study titled "Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer". This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor trea...
What is the current status of trial NCT02178163?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,020 participants. The study started on 2014-08-01. Estimated completion is 2027-07.
What conditions does trial NCT02178163 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT02178163?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT02178163?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02178163 being conducted?
This trial has 11 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02178163's enrollment target sits among peer trials
1,020 3rd of 23 higher than 21 of 23 other Stage IV Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
COMPLETED · NA
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI